πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

Vertex Pharmaceuticals (Australia) Pipeline

All ClinicalTrials.gov programs at Vertex Pharmaceuticals (Australia) β€” phase, modality, and trial IDs.

Programs
50

Quick answer

Vertex Pharmaceuticals (Australia) has 50 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Alyftrek 125 mg/50 mg/10 mg film-coated tablets, VX-121/VX-661/VX-561 Film-coated tablet

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  2. Biological/Vaccine

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 3 mab active

    1 trial

  3. CTX001

    Vertex Pharmaceuticals (Australia) Pty.

    Beta-Thalassemia

    phase 3 mab active

    1 trial

  4. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Sickle Cell Disease, Transfusion dependent thalassemia

    phase 3 small molecule active

    1 trial

  5. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-Dependent-Thalassemia

    phase 3 small molecule active

    1 trial

  6. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-dependent Ξ²-thalassemia (TDT)

    phase 3 small molecule active

    1 trial

  7. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, PLERIXAFOR, BUSULFAN

    Vertex Pharmaceuticals (Australia) Pty.

    Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  8. ELX/TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    19 trials

  9. Exa-cel

    Vertex Pharmaceuticals (Australia) Pty.

    Sickle Cell Disease

    phase 3 mab terminated

    1 trial

  10. IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials

  11. Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    16 trials

  12. Kalydeco 150 mg film-coated tablets, VX-770 Film-coated tablet, Kalydeco 75 mg film-coated tablets, VX-445/VX-661/VX-770 film-coated fixed-dose combination tablet, VX-770 Film-coated tablet, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, VX-445/VX-661/VX-770 fixed-dose combination tablet, Kaftrio 75 mg/50 mg/100 mg film-coated tablets

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  13. Kalydeco 75 mg film-coated tablets, Kalydeco 150 mg film-coated tablets, Kalydeco 59.5 mg granules in sachet, VX-445/VX-661/VX-770 film-coated fixed-dose combination tablet, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, VX-445/VX-661/VX-770 fixed-dose combination granules, VX-121/VX-661/VX-561 granules, VX-445/VX-661/VX-770 fixed-dose combination tablet, VX-121/VX-661/VX-561 Film-coated tablet, VX-121/VX-661/VX-561

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  14. LUM

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  15. Lumacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    6 trials

  16. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

    phase 3 small molecule completed

    1 trial

  17. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  18. MP-424

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial

  19. MP-424

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 3 small molecule completed

    2 trials

  20. PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-dependent Ξ²-thalassemia (TDT), Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  21. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 3 mab completed

    1 trial

  22. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Infection

    phase 3 small molecule terminated

    1 trial

  23. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  24. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Membranous Nephropathy

    phase 3 small molecule active

    1 trial

  25. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  26. Ribavirin

    Vertex Pharmaceuticals (Australia) Pty.

    Genotype 1 Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial

  27. SUZ

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 3 small molecule completed

    1 trial

  28. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 3 small molecule active

    3 trials

  29. Suzetrigine (SUZ)

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 3 small molecule completed

    1 trial

  30. TACROLIMUS, ALPN-303 solution for injection in pre-filled syringe, TACROLIMUS, TACROLIMUS, ALPN-303 solution for injection, Test IMP without active substance, ALPN-303 Solution for Injection in Pre-filled Pen

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Membranous Nephropathy

    phase 3 small molecule active

    1 trial

  31. TEZ

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials

  32. TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials

  33. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 3 small molecule terminated

    2 trials

  34. Tezacaftor/Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials

  35. VNZ/TEZ/D-IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    4 trials

  36. VX-121/TEZ/D-IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    6 trials

  37. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Proteinuric Kidney Disease

    phase 3 small molecule active

    1 trial

  38. VX-147 film-coated tablet, VX-147, Coated Placebo Tablet

    Vertex Pharmaceuticals (Australia) Pty.

    APOL1-mediated Proteinuric Kidney Disease (AMKD)

    phase 3 small molecule active

    1 trial

  39. VX-210

    Vertex Pharmaceuticals (Australia) Pty.

    Cervical Spinal Cord Injury

    phase 3 small molecule terminated

    1 trial

  40. VX-445/TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials

  41. VX-445/VX-661/VX-770 fixed-dose combination granules, VX-445/VX-661/VX-770 fixed-dose combination granules, Kalydeco 75 mg granules in sachet, Kalydeco 75 mg film-coated tablets, VX-770 75mg, VX-770 granules, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, Kaftrio 75 mg/50 mg/100 mg film-coated tablets, Kalydeco 150 mg film-coated tablets

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  42. VX-445/VX-661/VX-770 fixed-dose combination granules, VX-770 75mg, VX-770 granules, Kaftrio 75 mg/50 mg/100 mg granules in sachet, Kalydeco 50 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules, Kaftrio 60 mg/40 mg/80 mg granules in sachet, VX-770 50mg, Kalydeco 59.5 mg granules in sachet, Kalydeco 25 mg granules in sachet, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 granules, VX-445/VX-661/VX-770 granules, Ivacaftor 25 mg granules

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  43. VX-509

    Vertex Pharmaceuticals (Australia) Pty.

    Rheumatoid Arthritis

    phase 3 small molecule completed

    3 trials

  44. VX-659/TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    4 trials

  45. VX-661 Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials

  46. VX-661/Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  47. VX-770 granules, VX-445/VX-661/VX-770 fixed-dose combination granules, VX-445/VX-661/VX-770 granules, Kalydeco 25 mg granules in sachet, VX-445/VX-661/VX-770 granules, Kalydeco 50 mg granules in sachet

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  48. VX-809

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    4 trials

Frequently asked questions

How many pipeline programs does Vertex Pharmaceuticals (Australia) have?

50 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.